Edocera Sp. z o.o., a special purpose vehicle of Scope Fluidics, a life science company listed on the Warsaw Stock Exchange and developing innovative technologies for the medical diagnostics and healthcare market, has positively assessed the results of the verification of technologies selected for the project. The next goal is to develop a device prototype based on one of the technologies previously selected. The company plans to complete this stage of the project in 2026.
As part of the project, a product is being developed to enable prevention and ongoing diagnostics for people at risk of stroke. The product will consist of a wearable device and integrated software using artificial intelligence algorithms.
We are pleased that the analysis of the selected technologies and solutions has confirmed the course of action chosen by the EDOCERA team. Our next goal – which we plan to achieve in 2026 – is to develop a device prototype. Stroke often remains undetected for many hours, preventing rapid treatment and contributing to more than 12 million deaths annually. Approximately 100 million people are at high risk of stroke, while 1 billion are at elevated risk. We want our device, based on subtle signals, to be able to detect stroke at an early stage, within 4.5–6 hours, thus preventing 80% of stroke consequences and saving the lives of high-risk patients – says Piotr Garstecki, President of Scope Fluidics.
As a result of verifying the selected technologies and solutions, the Edocera team has recommended focusing prototype development on one of the technologies previously selected. Developing the prototype will require further R&D work to adapt the technology and develop solutions for use in the prototype, and subsequently in the final product, which will undergo market verification and certification. According to preliminary assumptions, the end user of the product will be private individuals (although other scenarios are also possible).
Funding from Scope Fluidics will be provided in installments depending on the progress and needs related to the project. According to preliminary estimates, the cost of developing the device prototype is approximately PLN 15 million, although this amount may change as the project develops and depending on Scope Fluidics’ financial situation.
Three key projects
In addition to the EDOCERA project, Scope Fluidics is currently developing and building the value of its flagship BACTEROMIC project – a rapid, comprehensive, and automated system for testing the susceptibility of bacterial infections to antibiotics. Meanwhile, the special purpose vehicle for the HYBOLIC project is developing a product for the early detection of the risk of metabolic syndrome, which can lead, among other things, to insulin resistance and type 2 diabetes, through monitoring the concentration of key biomarkers of these disorders, such as insulin and glucose.
